Biolife Solutions Inc (BLFS) — SEC Filings
Biolife Solutions Inc (BLFS) — 32 SEC filings. Latest: 8-K (May 7, 2026). Includes 13 8-K, 6 10-Q, 4 SC 13G/A.
View Biolife Solutions Inc on SEC EDGAR
Overview
Biolife Solutions Inc (BLFS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K/A filed on Apr 28, 2026: BioLife Solutions Inc. filed an amendment (10-K/A) to its annual report on April 28, 2026, for the fiscal year ending December 31, 2025. The filing includes the company's audited financial statements and other required disclosures. The company's principal executive offices are located in Bothell, WA
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 29 neutral, 3 mixed. The dominant filing sentiment for Biolife Solutions Inc is neutral.
Filing Type Overview
Biolife Solutions Inc (BLFS) has filed 13 8-K, 2 10-K/A, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G, 4 SC 13G/A, 1 DEFA14A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of BLFS's 23 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $77,429,000 |
| Net Income | $621,000 |
| EPS | N/A |
| Debt-to-Equity | 0.02 |
| Cash Position | $29,481,000 |
| Operating Margin | N/A |
| Total Assets | $392,081,000 |
| Total Debt | $7,492,000 |
Key Executives
- Dr. Jason Acker
- PEO
- Non-PEO NEO
- Dr. Robert J. Radu
Industry Context
BioLife Solutions operates within the life sciences sector, specifically focusing on the rapidly growing cell and gene therapy (CGT) market. This industry requires specialized bioproduction tools and services for manufacturing, distribution, and transportation of sensitive biologic materials. Key competitors offer a range of solutions, but BioLife differentiates itself with proprietary media, automated devices, and specialized containers designed to de-risk biologic manufacturing.
Top Tags
financials (7) · amendment (5) · 10-Q (5) · institutional-ownership (4) · Biotechnology (3) · annual-report (2) · Biopreservation (2) · corporate-governance (2) · shareholder-vote (2) · quarterly-report (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Fiscal Year End | 2025-12-31 | The period covered by the amended annual report. |
| Filing Date | 2026-04-28 | Date the amendment was accepted by the SEC. |
| Total Revenue (Q3 2025) | $28.067M | Increased 31.2% from $21.391M in Q3 2024 |
| Total Revenue (9M 2025) | $77.429M | Increased 30.1% from $59.539M in 9M 2024 |
| Net Income (Q3 2025) | $0.621M | Swung from a net loss of $1.703M in Q3 2024 |
| Net Loss (9M 2025) | ($15.665M) | Improved from a net loss of $32.643M in 9M 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $29.481M | Decreased significantly from $95.386M at Dec 31, 2024 |
| Operating Loss (9M 2025) | ($17.949M) | Increased from an operating loss of $5.019M in 9M 2024 |
| Common Shares Outstanding | 48,148,046 | As of October 30, 2025 |
| Q3 Revenue Growth | 31.2% | Year-over-year increase in total product, rental, and service revenue |
| 9M Revenue Growth | 30.1% | Year-over-year increase in total product, rental, and service revenue |
| Net Cash Provided by Operating Activities (9M 2025) | $15.199M | Increased from $6.786M in 9M 2024 |
| Product Revenue Q2 2025 | $25.3M | Increased from $23.8M in Q2 2024, showing 6.3% growth. |
| Service Revenue Q2 2025 | $4.1M | Decreased from $4.2M in Q2 2024, indicating a slight decline. |
| Rental Revenue Q2 2025 | $1.5M | Decreased from $1.7M in Q2 2024, showing a decline in this segment. |
Forward-Looking Statements
- {"claim":"Vanguard will continue to be a significant institutional holder of BioLife Solutions stock.","entity":"The Vanguard Group","targetDate":"Next 12 months","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Biolife Solutions Inc (BLFS)?
Biolife Solutions Inc has 32 recent SEC filings from Jan 2024 to May 2026, including 13 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BLFS filings?
Across 32 filings, the sentiment breakdown is: 29 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Biolife Solutions Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Biolife Solutions Inc (BLFS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Biolife Solutions Inc?
Key financial highlights from Biolife Solutions Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BLFS?
The investment thesis for BLFS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Biolife Solutions Inc?
Key executives identified across Biolife Solutions Inc's filings include Dr. Jason Acker, PEO, Non-PEO NEO, Dr. Robert J. Radu.
What are the main risk factors for Biolife Solutions Inc stock?
Of BLFS's 23 assessed filings, 0 were flagged high-risk, 10 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Biolife Solutions Inc?
Recent forward-looking statements from Biolife Solutions Inc include guidance on {"claim":"Vanguard will continue to be a significant institutional holder of BioLife Solutions stock.","entity":"The Van.